IONIS PHARMACEUTICALS INC — Form 8-K
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Ionis and AstraZeneca announced that eplontersen failed to meet the primary efficacy endpoint in the CARDIO-TTRansform Phase 3 trial (1,432 patients across 130 sites in 20 countries) for treating transthyretin-mediated amyloid cardiomyopathy. The composite outcome of cardiovascular mortality and recurrent CV events was not statistically significant versus placebo in the overall population; however, a prespecified subgroup of eplontersen monotherapy patients showed a nominally significant hazard ratio of 0.71. The drug demonstrated a favorable safety profile and large TTR reductions, but 81% of patients were on or initiated stabilizer therapy during the trial, which the company cites as explaining the negative result.
Why this rating
Major late-stage trial failure for a high-profile cardiometabolic program jointly developed with AstraZeneca; represents meaningful loss of near-term revenue potential in a large indication (~300k-500k patients globally). However, company maintains pipeline and cash flow targets; already has WAINUA approved for polyneuropathy indication.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.